Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory securities lawsuit

Replimune Securities Class Action Over FDA Rejection

Analysis based on 6 articles · First reported Sep 03, 2026 · Last updated Sep 22, 2026

Sentiment
-10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The lawsuit adds legal and reputational pressure on Replimune Group after the United States — Food and Drug Administration rejection already wiped out most of its market value, keeping downside risk elevated for the stock. Broader biotech sentiment may see modest caution as single-arm trial designs and accelerated approval pathways face heightened scrutiny from regulators and litigators.

biotechnology pharmaceuticals legal services

Pomerantz LLP announced a securities class action lawsuit against Replimune Group on behalf of investors who acquired Replimune securities during the Class Period. The suit alleges that Replimune and certain officers and/or directors engaged in securities fraud or other unlawful business practices. The underlying dispute stems from the United States — Food and Drug Administration's April 10, 2026 Complete Response Letter rejecting Replimune's Biologics License Application for RP1 in combination with Nivolumab. The United States — Food and Drug Administration cited deficiencies in the RPL-001-16 (IGNYTE) and RP1-104 (IGNYTE-3) studies, stating the evidence did not meet evidentiary standards for regulatory approval and that the RPL-001-16 trial was not an adequate and well-controlled investigation demonstrating substantial evidence of effectiveness. The agency also noted that Replimune had submitted objective response rate data from an early unplanned analysis of only 40 patients, 10 percent of the planned 400-patient enrollment, and that previously communicated study design concerns were not addressed. Following the news, Replimune shares fell 1.15 dollars, or 19.46 percent, to close at 4.76 dollars on April 10, 2026, and continued falling 3.06 dollars, or 64.29 percent, to close at 1.70 dollars on April 13, 2026. Investors have until October 5, 2026 to seek appointment as Lead Plaintiff. Pomerantz LLP is soliciting affected investors to join the action.

95 United States — Food and Drug Administration rejected biologics license application Replimune Group
70 Pomerantz LLP filed class action Replimune Group
40 Replimune Group issued press release
stock
Replimune Group is the target of the securities class action and the company whose BLA was rejected by the United States — Food and Drug Administration, triggering a roughly 84 percent two-day share price collapse. The litigation and regulatory setback severely damage its near-term prospects and investor confidence.
Importance 95.0 Sentiment -70.0
priv
Pomerantz LLP filed and is publicizing the class action against Replimune Group, seeking lead plaintiffs by October 5, 2026. The firm gains case visibility but faces no material market exposure.
Importance 70.0 Sentiment 5.0
govactor
The United States — Food and Drug Administration issued the Complete Response Letter rejecting Replimune Group's BLA for RP1 with Nivolumab, citing inadequate trial evidence. Its regulatory stance reinforces strict evidentiary standards for accelerated approval.
Importance 60.0 Sentiment 0.0
oth
Nivolumab was the combination partner in Replimune Group's rejected RP1 regimen; the rejection does not directly affect the drug's other approved uses.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.